Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2F2 | P24468 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12124198 | 0.76 | DYRK1A (0.46) | NR2F2IKBKBMAPTKDM4EPOLB | |
| SCHEMBL13683080 | 0.76 | DYRK1A (0.31) | DYRK1A | |
| SCHEMBL13162514 | 0.74 | HCAR2 (0.42) | NR2F2IKBKBMAPTKDM4EPOLB | |
| SCHEMBL17305931 | 0.74 | L3MBTL1 (0.32) | — | |
| SCHEMBL9261784 | 0.73 | NR2F2 (0.38) | NR2F2IKBKBMAPTKDM4EPOLB | |
| SCHEMBL13162512 | 0.73 | NR2F2 (0.38) | NR2F2IKBKBMAPTKDM4EPOLB | |
| SCHEMBL1120066 | 0.73 | NR2F2 (0.41) | NR2F2IKBKBMAPTKDM4EPOLB | |
| SCHEMBL19126608 | 0.73 | NR2F2 (0.32) | NR2F2 | |
| SCHEMBL13162566 | 0.73 | IKBKB (0.41) | NR2F2IKBKBMAPTKDM4EPOLB | |
| SCHEMBL14487631 | 0.72 | HCAR2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115551860-B | 2,4, 6-Trisubstituted pyrimidine compounds as ATR kinase inhibitors | 北京泰德制药股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-115135659-B | Morpholine derivative, and preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230391752-A1 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | CHULALONGKORN UNIVERSITY (TH) | 2023-12-07 | — | — | US | disclosed |
| US-20230212160-A1 | 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212160-A1 | 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| EP-4155307-A1 | 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2023-03-29 | — | — | EP | disclosed |
| US-20230037448-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | NOVIRA THERAPEUTICS, LLC | 2023-02-09 | — | — | US | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| CN-115551860-A | 2,4, 6-trisubstituted pyrimidine compounds as ATR kinase inhibitors | 北京泰德制药股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-115135659-A | Morpholine derivatives and preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2005061463-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1531822-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINE DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | Chemocentryx, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
| US-20040162282-A1 | Substituted piperazines | CHEMOCENTRYX, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20040082571-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2004-04-29 | — | — | US | disclosed |
| EP-1383747-A1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LIMITED (GB) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003105853-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2002088095-A1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LIMITED (GB) | 2002-11-07 | — | — | WO | disclosed |
| US-3957480-A | HERBICIDES | THE UPJOHN COMPANY (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391752-A1 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | GLS2, PYGL, CPS1 | NR2F2 4405/4885IKBKB 1317/4885MAPT 3568/4885 |
| US-20040082571-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | NR2F2 310/4885IKBKB 1307/4885MAPT 3524/4885 |
| US-20230212160-A1 | 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS | ATR, CHEK2, CHEK1 | NR2F2 1716/4885IKBKB 672/4885MAPT 2003/4885 |
| US-20040162282-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | NR2F2 310/4885IKBKB 1307/4885MAPT 3524/4885 |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | CRH, CRHR1, CRHR2 | NR2F2 326/4885IKBKB 1295/4885MAPT 3273/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | NR2F2 3264/4885IKBKB 1454/4885MAPT 1399/4885 |
| US-20230037448-A1 | FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES | DHODH, NQO2, DPYD | NR2F2 2772/4885IKBKB 1018/4885MAPT 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.